Tag:

Genzyme

Latest Headlines

Latest Headlines

Amicus jumps on upbeat data for Pompe drug

Amicus Therapeutics revealed its success in a small midstage study of its drug to enhance enzyme therapy in patients with the rare genetic disorder Pompe disease. On the back of the upbeat data, the biotech company's shares recovered some of the lost ground from news last month of a Phase III failure for its lead candidate.

Ex-Genzyme CEO to serve as Prosensa's strategic adviser

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

EMA committee shoots down Sanofi's cholesterol drug mipomersen

A European Medicines Agency panel handed down a negative opinion late this week on the antisense drug from Isis Pharmaceuticals for treating a genetic disease that causes blood cholesterol to jump, citing safety concerns such as signs of liver toxicity and cardiovascular risks in patients in clinical trials.

Ex-Genzyme CEO Termeer returns to his roots at biotech Prosensa

The former Genzyme CEO and chairman has joined the biotech Prosensa as a strategic adviser, bringing his experience in building Genzyme into a world leader in rare diseases.

NanoString draws $15.3M Series E for cancer Dx test launch

NanoString Technologies attracted $15.3 million in Series E financing, which it will use to advance the commercial launch of its debut breast cancer assay, navigate the U.S. regulatory approval process for its test and further its overall pipeline.

Targacept taps Stephen A. Hill to serve as president and CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Manufacturers return some drugs to market but shortages persist

There has been progress on the drug shortages front in the last few weeks with a couple of drugmakers saying manufacturing improvements have allowed them to again meet demand for two critical drugs. But as  The New York Times  points out, even with new drug shortages popping up at half the numbers of a year ago, there are still dozens of drugs in short supply.

Drug shortages improve but significant problem persists

The number of U.S. drugs that have been placed on a list of those in short supply is less than half what it was last year, only about 100 so far in 2012, compared with 221 when it peaked last year. The FDA says that it has prevented the shortage of about 150 drugs this year by working with the industry to find solutions to a potential dearth of a particular med.

Sanofi's new CSO to steer R&D reinvention drive from Cambridge, MA hub

Sanofi has plucked a chief scientific officer for its global R&D operations out of the top ranks at the National Institutes of Health. The pharma giant is placing him at an office in Cambridge, MA, highlighting once again its high hopes of reinventing drug research inside the rich scientific environment found in the booming Massachusetts biotech hub.

Genzyme manufacturing upgrades again paying off

Genzyme's manufacturing improvements continue to pay off, allowing it to return to the market with a full supply of its thyroid cancer treatment, Thyrogen.